Jordi Rodon

Summary

Affiliation: Cancer Therapy and Research Center
Country: USA

Publications

  1. ncbi request reprint Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
  2. doi request reprint Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    J Clin Oncol 27:5800-7. 2009
  3. doi request reprint A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 69:825-34. 2012
  4. doi request reprint Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
  5. ncbi request reprint A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
    Jordi Rodon
    Authors Affiliations Vall d Hebron Institut d Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania University of Leicester, Leicester, United Kingdom University Hospital of Zürich, Zurich, Switzerland Memorial Sloan Kettering Cancer Center, New York, New York Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas Novartis Institutes for BioMedical Research, Cambridge, Massachusetts and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
    Clin Cancer Res 20:1900-9. 2014
  6. ncbi request reprint Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Cancer Chemother Pharmacol 74:77-84. 2014

Detail Information

Publications6

  1. ncbi request reprint Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
    ..This provided the rationale for the three-times weekly treatment explored in this protocol...
  2. doi request reprint Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    J Clin Oncol 27:5800-7. 2009
    ..To determine the maximum-tolerated dose (MTD) and to assess the safety, pharmacokinetics, and evidence of antitumor activity of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 (IGF-1R)...
  3. doi request reprint A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 69:825-34. 2012
    ..The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced non-small cell lung cancer...
  4. doi request reprint Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
    ....
  5. ncbi request reprint A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
    Jordi Rodon
    Authors Affiliations Vall d Hebron Institut d Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania University of Leicester, Leicester, United Kingdom University Hospital of Zürich, Zurich, Switzerland Memorial Sloan Kettering Cancer Center, New York, New York Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas Novartis Institutes for BioMedical Research, Cambridge, Massachusetts and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
    Clin Cancer Res 20:1900-9. 2014
    ....
  6. ncbi request reprint Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Cancer Chemother Pharmacol 74:77-84. 2014
    ..Melanomas are vascular tumors with a high incidence of BRAF mutations driving tumor proliferation. Complete inhibition of vascular endothelial growth factor (VEGF) signaling has potential for enhanced antitumor efficacy...